Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.

Abstract

Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. This article reviews key efficacy and safety data arising from pivotal teriflunomide studies that demonstrate the utility in treating both treatment-naïve patients and those previously treated with another disease-modifying therapy who, for a variety of reasons, may require an alternative treatment.

• Authors: Aaron E Miller
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Vol. 11 Issue 2 Pg. 181-94 (Feb 2015) ISSN: 1744-8409 [Electronic] England
• PMID: 25511008 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Crotonates
• Hydroxybutyrates
• Nitriles
• Toluidines
• teriflunomide

Topics

• Crotonates (adverse effects, therapeutic use)
• Humans
• Hydroxybutyrates
• Multiple Sclerosis (drug therapy)
• Nitriles
• Recurrence
• Toluidines (adverse effects, therapeutic use)